Key Takeaways; Cannabis Sector
- Village Farms Posted Record Cannabis Revenue as International Exports Surged 75%
- Auxly Cannabis Delivered Record Q3 Revenue as Adjusted EBITDA Climbed 29%
Key Takeaways; Psychedelic Sector
- Definium Therapeutics Reported Strong Q3 Results as DT120 Advanced Towards Potential 2027 Approva
- NRx Pharmaceuticals Launched U.S.-Made Preservative-Free Ketamine Amid Ongoing Supply Shortage
- GH Research Advanced GH001 Towards Pivotal Trials in Depression Following Positive Clinical Results
- Optimi Health Established Australian Subsidiary to Strengthen Psychedelic Drug Distribution
Below is a weekly roundup of what happened this week in the cannabis and psychedelic sectors. In this ever-evolving landscape, we explore the major developments and groundbreaking initiatives happening among companies operating in these industries; from advancements in medical research, therapeutic applications to shifts in legal frameworks and current market trends.
Top Marijuana Companies for the Week
#1: Village Farms
Village Farms International Inc. (NASDAQ: VFF) reported record cannabis revenue of US$55 million for the third quarter ended September 30, 2026, representing a 3% increase from $53.5 million in the same period last year. Consolidated net sales remained relatively flat at $66.9 million, compared with $66.7 million in Q3 2025, while net income attributable to shareholders reached $10 million, or $0.08 per share.
The company’s international cannabis business was a major growth driver, with export sales increasing 75% year-over-year to a record $20.8 million, up from $11.9 million. According to Village Farms, the growth was primarily driven by continued expansion in shipments to Germany, reinforcing the company’s position as one of the leading medical cannabis exporters to Europe. International exports accounted for approximately 31% of consolidated revenue, compared with 18% a year earlier.
Canadian branded cannabis sales declined 6% year-over-year to $25.3 million, while non-branded sales fell to $3.3 million from $7.3 million. Despite the decline, Village Farms said it maintained its top five overall market share position in Canada, gaining further share in convenience product categories, particularly vapes and infused pre-rolls. According to the company, its brand portfolio also retained a top 10 position across all major national product categories.
Meanwhile, U.S. cannabis sales decreased 16% to $2.8 million, reflecting weaker direct-to-consumer demand amid competition from unregulated hemp-derived products and state-level regulatory restrictions. Sales from the Netherlands branded cannabis market also declined 21% to $2.8 million.
The company’s President and CEO, Michael DeGiglio, highlighted the strength of the company’s expanding international business and continued profitability. “Our third quarter results were driven by record cannabis revenues of $55 million and approximately 43% of cannabis sales from some of the world’s most attractive and fastest growing international markets,” he said, adding that the company had delivered its sixth consecutive quarter of positive net income and earnings per share.
Village Farms reported it is also advancing several capacity expansion initiatives to support future growth. According to the company, its Delta 2 greenhouse expansion in British Columbia remains on schedule for completion in the first quarter of 2027. In the Netherlands, the company reported that its Phase II Groningen facility is now fully planted and is expected to contribute to stronger sales growth beginning in the fourth quarter of 2026 and throughout 2027.
Looking ahead, DeGiglio expressed confidence in the company’s production expansion plans and international growth prospects. He noted that the Delta 2 expansion and the Netherlands facility are expected to support stronger organic revenue growth, while the company continues to pursue opportunities in additional European markets.
#2: Auxly Cannabis
Auxly Cannabis Group Inc. (TSX: XLY) (OTCQB: CBWTF) reported record financial results for the third quarter of 2026, posting a 24% year-over-year increase in net revenue to $49.5 million for the three months ended September 30, 2026.
The Canadian cannabis company also recorded gross profit of $30.7 million, while its gross margin on finished cannabis inventory sold remained stable at 56%. Adjusted EBITDA increased 29% to $15.8 million, representing 32% of net revenue. Meanwhile, cash flow from operations before working capital changes rose 28% to $14.8 million.
Net income reached $13.6 million, compared with $20.5 million in the same period last year, representing a 34% decline. However, the company noted that its third-quarter 2025 results included an after-tax gain of $8.1 million from the Imperial Debenture Settlement. Excluding this gain and fair value adjustments on biological transformation and inventory, Auxly’s net income increased by $4.4 million, or 70%, year-over-year.
According to the company, revenue growth was primarily driven by higher sales volumes across its core product portfolio, particularly dried flower, pre-rolls and vape products. Improved pricing across its flower portfolio also contributed to the increase, partially offset by continued price compression in vape products.
Auxly CEO, Hugo Alves, described the quarter as another record period for the company, highlighting its ability to combine revenue growth with strong profitability. “Auxly delivered another record quarter in Q3 2026, with strong growth across our key financial measures while maintaining industry-leading profitability,” Alves said. He also pointed to the company’s stable 56% gross margin as evidence of the strength of its business model and operating efficiency.
Looking ahead, Auxly intends to strengthen its position in Canada’s cannabis market through continued product innovation, operational improvements and increased production capacity at its Leamington facility in Ontario. The company stated it plans to invest up to $30 million in capital projects through the end of 2028, with the investments expected to increase production capacity by approximately 30% compared with 2025 levels.
Top Psychedelic Companies for Week
#1: Definium Therapeutics
Definium Therapeutics, Inc. (NASDAQ: DFTX) reported encouraging third-quarter 2026 financial results, highlighting significant clinical progress across its psychedelic-based treatment pipeline, particularly DT120 ODT, which is being developed for generalized anxiety disorder (GAD) and major depressive disorder (MDD).
In its November 9 earnings announcement, the New York-based biopharmaceutical company reported a third-quarter loss of $0.46 per share, beating analyst expectations of a $0.56 loss per share. The company also reported a net loss of $51 million, down from $67.3 million during the same period last year.
A major highlight was the positive topline results from two Phase 3 trials, Voyage and Panorama, evaluating DT120 ODT in patients with GAD. According to the company, both studies met their primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful improvements in anxiety symptoms. Additionally, DT120 ODT received the FDA’s Breakthrough Therapy designation for MDD following positive Phase 3 results from the Emerge study. Definium said that it remains on track to submit its New Drug Application (NDA) for DT120 ODT in the first half of 2027.
CEO Rob Barrow expressed confidence in the programme’s progress, stating: “Together with our previously reported results, these findings demonstrate consistent, clinically meaningful results across three Phase 3 studies in GAD and MDD, reinforcing our confidence in DT120 ODT’s potential to address significant unmet needs across both conditions.”
Financially, Definium reported approximately $1.05 billion in cash, cash equivalents and investments as of September 30, 2026, compared with $411.6 million at the end of 2025. Based on its current operating plans and anticipated milestones, management expects its financial resources to fund operations into 2030, providing substantial runway to advance its clinical programmes and prepare for potential commercialisation.
The company said it is also expanding its commercial infrastructure in anticipation of DT120 ODT’s potential approval. Plans include its first Commercial Day in the first half of 2027, where management intends to outline the drug’s market opportunity and commercialisation strategy. Meanwhile, the company is preparing to initiate a Phase 3 study of DT120 in post-traumatic stress disorder (PTSD) in 2027.
#2: NRx Pharmaceuticals
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) announced it had commenced sales of its newly approved preservative-free ketamine injection, marking an important step towards addressing the longstanding shortage of ketamine in the United States. Announced on November 11, 2026, the launch introduced a U.S.-manufactured alternative to existing injectable ketamine products, which have faced supply shortages since 2018.
Unlike currently available U.S. ketamine injections, which contain the preservative benzethonium chloride (BZT), NRx’s stated that its formulation is preservative-free. According to the company, the product also features an innovative blow-fill-seal vial with a needle-free, luer-lock connection that attaches directly to a sterile syringe. This design aims to improve handling efficiency, reduce needlestick risks among healthcare professionals and eliminate the need for sharps disposal associated with traditional glass vials.
To support the commercial launch, NRx sated it had deployed a trained and certified 17-person sales team with extensive experience in the sterile injectable market. The representatives already maintain relationships with hospital purchasers and group purchasing organisations responsible for approximately 80% of current U.S. ketamine sales. CEO Jonathan Javitt highlighted the commercial advantage of this approach, stating: “By enlisting seasoned sales representatives who already sell sterile injectable drugs, we are able to drive considerable efficiency in costs of sales and marketing.”
The company is targeting initial supply agreements and preorders for late 2026, with product shipments expected to begin in January 2027. NRx anticipates gross and net sales margins exceeding 50%, supported by the lower manufacturing costs associated with BFS technology. The company estimates that the process can reduce manufacturing costs to less than 20% of the hospital sales price, compared with potentially 70% or more for traditional glass-vial production.
In a separate announcement on November 12, NRx Pharmaceuticals confirmed that it will release its third-quarter 2026 financial results before the market opens on November 17. Additionally, NRx said that management will also host a conference call at 8:00 a.m. ET to discuss the financial performance and provide a corporate update. Investors will be able to access the live webcast through the company’s investor relations website.
#3: GH Research
GH Research PLC (NASDAQ: GHRS) reported its third-quarter 2026 financial results alongside significant progress in the clinical development of GH001, its investigational mebufotenin-based treatment for depression. The company said it is preparing to advance the treatment into pivotal clinical trials for treatment-resistant depression (TRD), following positive regulatory feedback from the U.S. Food and Drug Administration (FDA).
A key development during the quarter was the completion of the Phase 1 GH001-HV-106 trial, which evaluated a novel Aerosol Delivery System designed to improve dosing consistency. The company stated the results support the use of a single fixed dose per treatment visit, replacing the previous approach of administering up to three individually adjusted doses. According to GH Research, the new delivery system could allow treatment visits to be completed in approximately one hour, potentially simplifying administration in clinical practice.
The company also reported it had received positive initial feedback from the FDA regarding its proposed pivotal programme in TRD. GH Research expects to hold an End-of-Phase 2 meeting with the agency in the first quarter of 2027, with the aim of initiating pivotal trials shortly afterwards, subject to final regulatory alignment. The planned studies will compare different fixed-dose groups against placebo, with treatment outcomes primarily assessed using changes in the Montgomery-Åsberg Depression Rating Scale.
Beyond TRD, GH Research said it is advancing GH001 for postpartum depression (PPD). In its open-label Phase 2a study involving ten patients, the company reported that all participants achieved remission within two hours of treatment, with remission maintained through Day 8 following a single treatment day. The trial also met its primary endpoint. The company said it is targeting the initiation of a pivotal PPD programme in the second half of 2027.
Commenting on the findings, Kristina M. Deligiannidis, MD, of the Feinstein Institutes for Medical Research at Northwell Health, highlighted the potential benefits for new mothers, stating: “Women with postpartum depression need treatments that work quickly and ask little of them at a time when they are caring for a newborn.” She added that a single-dose treatment administered during an approximately one-hour visit could better accommodate the needs of women experiencing postpartum depression.
Financially, GH Research reported cash, cash equivalents and marketable securities of $350.6 million as of September 30, 2026, compared with $280.7 million at the end of 2025. Research and development expenses totaled $10.1 million, while general and administrative expenses amounted to $5.3 million. The company reported a quarterly net loss of $12.5 million, equivalent to $0.18 per share, compared with a $14 million loss, or $0.23 per share, in the same period last year.
#4: Optimi Health
Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) recently announced the establishment of Optimi Australia Pty Ltd, a wholly owned subsidiary dedicated to strengthening the company’s commercial presence and expanding its distribution network across Australia. The new entity will oversee sales, distribution and relationships with authorized prescribers, clinics and pharmacies throughout the country.
Through Optimi Australia, the company aims to increase access to its finished pharmaceutical products, including naturally derived 5mg psilocybin capsules and 40mg and 60mg MDMA capsules. The products are manufactured at Optimi’s Health Canada-licensed, GMP-compliant facility in Princeton, British Columbia, and supplied to eligible healthcare providers under Australia’s Authorized Prescriber Scheme.
To lead the expansion, Optimi said it had appointed Adrian Jones as Director of Australian Operations. According to the company, Jones brings more than 15 years of pharmaceutical industry experience, most recently serving as Associate Director and Head of Sales and Marketing for Bristol Myers Squibb’s Australian oncology and cardiovascular portfolios. His previous experience also includes positions with Eli Lilly and Hospira.
Optimi CEO, Dane Stevens, highlighted Australia’s importance to the company’s commercial strategy, stating, “Australia is our first commercial market, and we believe demand from authorized prescribers there continues to grow.” He added that establishing a local team under Jones’ leadership would strengthen the company’s ability to support the expanding market. Jones said his immediate priority would be to understand clinicians’ needs and help them deliver treatments as efficiently and effectively as possible.
The establishment of Optimi Australia represents a strategic step in the company’s efforts to expand its international commercial operations and strengthen relationships with healthcare providers. With a dedicated local distribution and business development team, Optimi aims to build on its existing presence in Australia’s regulated psychedelic medicine market while increasing access to its psilocybin- and MDMA-based products.


